|
| Home : Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol |
|
Jun 26
2020 |
Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol |
|
NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S.... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol-301084188.html |
| |
|
Related News
|
» Tune In Tomorrow - Global Citizen And The European Commission's 'Global Goal: Unite For Our Future'; Global Goal: Unite For Our Future-The Concert Broadcast Special To Premiere Tomorrow, Saturday, June 27, 2020 Following Global Goal: Unite For Our Future-The Summit
» Preferred Luxury Real Estate, la prestigiosa Inmobiliaria Boutique reafirma su liderazgo en la industria de los Bienes Raíces en Cancún
|
|
|
